Carlsmed Leads Personalized Spine Surgery Innovation

Got story updates? Submit your updates here. ›

Carlsmed (NASDAQ:CARL) is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions. The company's aprevo Technology Platform provides customized surgical plans and interbody implants tailored to each patient's unique anatomy and pathology, aiming to optimize spinal alignment and reduce the need for revision surgeries.

Why it matters

Traditional spine fusion surgery often lacks robust pre-operative planning and uses one-size-fits-all implants, leading to poor outcomes and high revision rates. Carlsmed's personalized approach leverages AI and 3D modeling to deliver better surgical results and reduce the significant economic burden of revision procedures.

The details

The aprevo Technology Platform includes AI-enabled software for pre-operative planning, custom-designed interbody implants, and single-use surgical instruments. It is designed to address the limitations of traditional spine fusion by providing personalized surgical plans and implants that are tailored to each patient's unique anatomy. Carlsmed's solutions are 510(k) cleared by the FDA for lumbar fusion and are in development for cervical fusion.

• Carlsmed received FDA 510(k) clearance for its aprevo interbody implants for cervical interbody fusion surgeries in November 2024.
• Carlsmed plans to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026.

What’s next

Carlsmed is currently conducting a 338-patient study, the COMPASS Registry, to track clinical outcomes from procedures using the aprevo Technology Platform in both degenerative disc disease and adult spinal deformity patients.